The 6 most recent market catalysts affecting $QURE, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 2, 2026
Corporate Catalyst
Bullish
Impact 85
uniQure shares are trading higher after the company announced the submission of a Biologics License Application to the FDA for the accelerated approval of ifezuntirgene inilparvove. The company submitted its Marketing Authorization Application for ifezuntirgene inilparvovec to the MHRA.
This headline represents a significant corporate catalyst for uniQure. The submission of a BLA to the FDA for accelerated approval and an MAA to the MHRA indicates that the company…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 55
Wells Fargo Maintains Overweight on uniQure, Raises Price Target to $75
Wells Fargo analyst Yanan Zhu maintained an Overweight rating on uniQure (QURE) and raised the price target from $60 to $75. This analyst action signals increased confidence in the…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 65
Wolfe Research Upgrades uniQure to Outperform, Announces $65 Price Target
Wolfe Research analyst Rudy Li upgraded uniQure (QURE) from Peer Perform to Outperform and announced a $65 price target. This is a significant positive signal from a reputable rese…
Jul 30, 2026
Corporate Catalyst
Bearish
Impact 55
Barclays Maintains Overweight on uniQure, Lowers Price Target to $60
Barclays analyst Eliana Merle reiterated an 'Overweight' rating for uniQure, signaling continued confidence in the company's long-term prospects. However, the simultaneous reductio…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 75
uniQure shares are trading higher after the company reported better-than-expected Q2 sales results.
This headline represents a significant corporate catalyst for uniQure, as better-than-expected sales directly impact investor perception of the company's financial health and futur…
Jul 29, 2026
Corporate Catalyst
Bearish
Impact 92
uniQure Q2 EPS $(1.22) Misses $(0.82) Estimate, Sales $5.800M Beat $5.467M Estimate
uniQure's Q2 earnings report presents a mixed bag for investors. The substantial miss on EPS, with losses widening significantly year-over-year, is a primary concern and could lead…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.